FedPhase 1NCT01503450
Bioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fed Condition
A Phase 1 study testing Olanzapine OD Tablets 5 mg in people with Fed, run by Dr. Reddy's Laboratories Limited at 1 site in India.
Trial summary
The purpose of this study is to compare the single oral dose bioequivalence of olanzapine 5 mg OD tablets with Zyprexa Zydis 5 mg tablets under fed conditions and to monitor adverse events and ensure safety of subjects. Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Fed
- What is being tested?
- Olanzapine OD Tablets 5 mg
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 26 participants
- Where
- 1 siteIndia
- Study dates
- Nov 2006to Dec 2006
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy human subjects within the age range of 18 to 45 years
- Non-smokers since at least six months
- Willingness to provide written informed consent to participate in the study
- Body-mass index of ≥18.5 kg/m2 and ≤ 24.9 kg/m2, with body weight not less than 50 kg
- Absence of significant disease or clinically significant abnormal laboratory values on laboratory evaluations, medical history or physical examination during the screening
- Normal 12-lead ECG or one with abnormality considered to be clinically insignificant
Show all 12Show fewer
- Normal chest X-ray PA view
- Comprehension of the nature and purpose of the study and compliance with the requirement of the protocol
- Female Subjects
- of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams. Jellies, diaphragm, intrauterine device (IUD), or abstinence, or
- postmenopausal for at least 1 year, or
- surgically sterile (bilateral tubal ligation. bilateral oophorectomy, or hysterectomy has been performed on the subject
Who cannot join
- Personal / family history of allergy or hypersensitivity to olanzapine or allied drugs
- Past history of anaphylaxis or angioedema
- Any major illness in the past three months or any clinically significant ongoing chronic medical illness e.g. congestive heart failure, hepatitis, pancreatitis etc.
- Presence of any clinically significant abnormal values during screening e.g. significant abnormality of liver Function Test (LFT), Renal (kidney) Function Test (RFT), etc.
- Any cardiac, renal or liver impairment, any other organ or system impairment
- History of seizure or psychiatric disorders
Show all 19Show fewer
- Presence of disease markers of HIV 1 and 2, and hepatitis Band C virus
- Consumption of alcohol for more than two years, or consumption of more than three alcoholic drinks per day or consumption of alcohol within 48 hours prior to dosing and during the study [one drink is equal to one unit of alcohol [ one glass Wine, half plnt boor, and one measure (one ounce) of spirit).
- Consumption of xanthine containing derivatives (coffee, tea, cola drinks. chocolate) within 48 hours before check-in of each period
- Use of any recreational drug or a history of drug addiction
- Participation in any clinical trial within the past 3 months
- Inaccessibility of veins in left and right arm
- Donation of blood (one unit or 350 mL) within 3 months prior to receiving the first dose of study medication
- Receipt of any prescription drug therapy within four weeks or over-the-counter (OTC) drugs within two weeks prior to receiving the first dose of study medication or repeated use of drugs Within the last four weeks
- An unusual diet, for whatever reason e.g. low sodium diet, for two weeks prior to receiving any medication and through out subject's participation in the study
- Consumption of grapefruit- containing food or beverages within 7 days prior to receiving the first dose of study medication in both the periods
- Recent history of dehydration from diarrhea, vomiting or any other reason within a period of 24 hours prior to the study
- Female volunteers demonstrating a positive pregnancy screen or currently breast-feeding
- Having an occupation or requirement of driving a vehicle or operate a complex machinery before 21 days of taking the drug in both periods
Trial locations and contacts
1 site in 1 country.
About this study
Official title: An Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Bioequivalence Study of Olanzapine 5 mg OD Tablets With Zyprexa Zydis 5 mg Tablets in Healthy Subjects Under Fed Conditions
The purpose of this study is to compare the single oral dose bioequivalence of olanzapine 5 mg OD tablets with Zyprexa Zydis 5 mg tablets under fed conditions and to monitor adverse events and ensure safety of subjects.
Read the detailed description
An open label, balanced, randomized, two treatment, two-sequence, two-period, single-dose, crossover comparative bioequivalence study of Olanzapine 5 mg OD Tablets, of Dr. Reddy's Laboratories Limited and Zyprexa Zydis 5 mg Tablets of Cardinal Health in healthy, human subjects under fed conditions.
- Conditions
- Fed
- Being tested
- Olanzapine OD Tablets 5 mg
- Medical subject headings
- Lecithin Cholesterol Acyltransferase Deficiency
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Olanzapine OD Tablets 5 mgDrug
Also called Zyprexa Zydis
Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
| Study group | Role | What they receive |
|---|---|---|
| Olanzapine OD Tablets 5 mg | Experimental | Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited Receives: Drug: Olanzapine OD Tablets 5 mg |
| Zyprexa Zydis 5 mg Tablets | Active comparator | Zyprexa Zydis 5 mg Tablets of Cardinal Health, UK Receives: Drug: Olanzapine OD Tablets 5 mg |
What is being measured
The primary outcome is the main question the study is designed to answer.
Bioequivalence is based on Cmax and AUC parameters
Measured: 2 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jan 2012 (estimated)
- Study startNov 2006
- Primary completionDec 2006
- Study completionDec 2006
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for FedStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 26 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dr. Reddy's Laboratories Limited
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Dr. Ghanashyam Rao, MBBS, Principal investigator, Wellquest Clinical Research
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01503450
- Sponsor's protocol ID
- BE-171-OLAN-2006
- Status last verified
- Jan 2012
- First submitted
- 2 Jan 2012
- Last updated
- 5 Jan 2012
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 5 Jan 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Bioequivalence Study of Olanzapine 5 mg OD Tablets With Zyprexa Zydis 5 mg Tablets in Healthy Subjects Under Fed Conditions
- ClinicalTrials.gov ID
- NCT01503450
- Acronym / sponsor ID
- BE-171-OLAN-2006
- Conditions
- Fed
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 26 participants (actual)
- Lead sponsor
- Dr. Reddy's Laboratories LimitedIndustry (pharma, biotech, devices)
- Study start
- Nov 2006
- Primary completion
- Dec 2006 (actual)
- Study completion
- Dec 2006 (actual)
- First posted
- 4 Jan 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to compare the single oral dose bioequivalence of olanzapine 5 mg OD tablets with Zyprexa Zydis 5 mg tablets under fed conditions and to monitor adverse events and ensure safety of subjects.
Detailed description
An open label, balanced, randomized, two treatment, two-sequence, two-period, single-dose, crossover comparative bioequivalence study of Olanzapine 5 mg OD Tablets, of Dr. Reddy's Laboratories Limited and Zyprexa Zydis 5 mg Tablets of Cardinal Health in healthy, human subjects under fed conditions.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Olanzapine OD Tablets 5 mg | Experimental | Drug: Olanzapine OD Tablets 5 mgOlanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited |
| Zyprexa Zydis 5 mg Tablets | Active comparator | Drug: Olanzapine OD Tablets 5 mgZyprexa Zydis 5 mg Tablets of Cardinal Health, UK |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (12 listed)
- Healthy human subjects within the age range of 18 to 45 years
- Non-smokers since at least six months
- Willingness to provide written informed consent to participate in the study
- Body-mass index of ≥18.5 kg/m2 and ≤ 24.9 kg/m2, with body weight not less than 50 kg
- Absence of significant disease or clinically significant abnormal laboratory values on laboratory evaluations, medical history or physical examination during the screening
Key exclusion criteria (19 listed)
- Personal / family history of allergy or hypersensitivity to olanzapine or allied drugs
- Past history of anaphylaxis or angioedema
- Any major illness in the past three months or any clinically significant ongoing chronic medical illness e.g. congestive heart failure, hepatitis, pancreatitis etc.
- Presence of any clinically significant abnormal values during screening e.g. significant abnormality of liver Function Test (LFT), Renal (kidney) Function Test (RFT), etc.
- Any cardiac, renal or liver impairment, any other organ or system impairment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Olanzapine OD Tablets 5 mgAlso: Zyprexa ZydisOlanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited | Drug | Olanzapine OD Tablets 5 mg, Zyprexa Zydis 5 mg Tablets |
Primary outcome
Bioequivalence is based on Cmax and AUC parameters
Time frame: 2 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jan 2012.
Related trials for Fed
RecruitingPhase 2
A Study of the Safety and Efficacy of TRTL-913 in Healthy Volunteers (Part A) and in Adults With Tinnitus (Part B)
Tinnitus
Not yet recruitingPhase 1
A Phase 1, Open-Label, Two-Stage, Food Effect Study to Assess the Safety, Tolerability, and Pharmacokinetics of EI-1071 Under Fasted or Fed Conditions in Healthy Volunteers
Food Effect in Healthy Volunteers
Not yet recruiting
Replacing Meat With Legumes in a Mediterranean Diet
Healthy Adult Participants
Not yet recruitingPhase 2
Tafenoquine Drug Levels in Small Children
Plasmodium Vivax Malaria, Vivax Malaria
Active, not recruiting
Early Protein Supplementation in Extremely Preterm Infants Fed Human Milk
Prematurity; Extreme, Feeding Disorder Neonatal
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dr. Ghanashyam Rao, MBBS principal investigator
Wellquest Clinical Research
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Olanzapine OD Tablets 5 mg in people with Fed, run by Dr. Reddy's Laboratories Limited at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Jan 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Bioequivalence is based on Cmax and AUC parameters (time frame: 2 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jan 2012.